|
|
利培酮治疗精神分裂症的临床效果及经济性研究进展
|
Abstract:
精神分裂症是一种病理机制不明的慢性高致残性精神疾病，主要临床特征表现为思维、情感及行为紊乱和认知功能明显受损。现阶段药物治疗仍是临床上治疗精神分裂症的主流方法。第二代抗精神病药又称非典型抗精神病药，相对来说对患者认知功能影响较小，副作用较少，患者的依从性较好，是目前应用最广泛的抗精神病药物。本文就利培酮治疗精神分裂症的临床效果及经济性研究作一综述。
Schizophrenia is a chronic and highly disabling mental disease with unknown pathological mecha-nism. The main clinical characteristics are thinking, emotion and behavior disorders and obvious impairment of cognitive function. At present, drug therapy is still the mainstream method in clini-cal treatment of schizophrenia. Second-generation antipsychotics, also known as atypical antipsy-chotics, have relatively little impact on patients’ cognitive function, fewer side effects, and better patient compliance, making them the most widely used antipsychotics at present. This article re-views the clinical effect and economic study of risperidone in the treatment of schizophrenia.
| [1] | Dong, M., Wang, S.B., Wang, F., et al. (2019) Suicide-Related Behaviours in Schizophrenia in China: A Comprehensive Meta-Analysis. Epidemiology and Psychiatric Sciences, 28, 290-299. https://doi.org/10.1017/S2045796017000476 |
| [2] | Brannan, S.K., Sawchak, S., Miller, A.C., et al. (2021) Musca-rinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. The New England Journal of Medicine, 384, 717-726.
https://doi.org/10.1056/NEJMoa2017015 |
| [3] | Pahwa, M., Sleem, A., Elsayed, O.H., et al. (2021) New Antipsy-chotic Medications in the Last Decade. Current Psychiatry Reports, 23, Article No. 87. https://doi.org/10.1007/s11920-021-01298-w |
| [4] | Cecilio, á. (2022) Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. Advances in Therapy, 39, 4875-4891. https://doi.org/10.1007/s12325-022-02299-8 |
| [5] | Katja, K., Christine, R., Sandra, S., et al. (2011) Risperidone versus Other Atypical Antipsychotics for Schizophrenia. The Cochrane Database of Systematic Reviews, No. 1, CD006626. |
| [6] | Edwards, J.G. (1994) Risperidone for Schizophrenia. BMJ (Clinical Research Ed.), 308, 1311-1312.
https://doi.org/10.1136/bmj.308.6940.1311 |
| [7] | Lisoway, A.J., Chen, C.C., Zai, C.C., et al. (2021) Toward Per-sonalized Medicine in Schizophrenia: Genetics and Epigenetics of Antipsychotic Treatment. Schizophrenia Research, 232, 112-124.
https://doi.org/10.1016/j.schres.2021.05.010 |
| [8] | Sameer, J. and Mandy, J. (2022) Schizophrenia. The Lancet, 399, 473-486.
https://doi.org/10.1016/S0140-6736(21)01730-X |
| [9] | Michalczyk, A., Tyburski, E., Podwalski, P., et al. (2022) Serum Inflammatory Markers and Their Associations with White Matter Integrity of the Corpus Callosum in Schizophre-nia Patients and Healthy Controls. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 116, Article ID: 110510.
https://doi.org/10.1016/j.pnpbp.2022.110510 |
| [10] | Chopko, T.C. and Lindsley, C.W. (2018) Classics in Chemical Neuroscience: Risperidone. ACS Chemical Neuroscience, 9, 1520-1529. https://doi.org/10.1021/acschemneuro.8b00159 |
| [11] | Ahmad, A.B., Gaurav, G., Obaid, A., et al. (2023) Neuro-pharmacological Effect of Risperidone: From Chemistry to Medicine. Chemico-Biological Interactions, 369, Article ID: 110296. https://doi.org/10.1016/j.cbi.2022.110296 |
| [12] | An, R.J., Seo, S.M., Jung, S.H., et al. (2020) Inhibition by the Atypical Antipsychotic Risperidone of Voltage-Depen- dent K+ Channels in Rabbit Coronary Arterial Smooth Mus-cle Cells. European Journal of Pharmacology, 874, Article ID: 173027. https://doi.org/10.1016/j.ejphar.2020.173027 |
| [13] | Mannens, G., Huang, M.L., Meuldermans, W., et al. (1993) Absorption, Metabolism, and Excretion of Risperidone in Humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 21, 1134-1141. |
| [14] | Filip, M., Nikola, B., Zorana, P., et al. (2020) Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status with Antidepressant and Antipsychotic Exposure: A Systematic Re-view and Meta-Analysis. JAMA Psychiatry, 78, 270-280. https://doi.org/10.1001/jamapsychiatry.2020.3643 |
| [15] | Correll, C.U., Rubio, J.M. and Kane, J.M. (2018) What Is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People with Schizophrenia? World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 17, 149-160. https://doi.org/10.1002/wps.20516 |
| [16] | Cheng, Z., Yuan, Y., Han, X., et al. (2019) An Open-Label Randomised Comparison of Aripiprazole, Olanzapine and Risperi-done for the Acute Treatment of First-Episode Schizophrenia: Eight-Week Outcomes. Journal of Psychopharmacology, 33, 1227-1236. https://doi.org/10.1177/0269881119872193 |
| [17] | Marcos, G., María, J.P., María, J., et al. (2020) Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. The International Journal of Neuropsychopharmacology, 23, 217-229.
https://doi.org/10.1093/ijnp/pyaa004 |
| [18] | 刘明秋, 黄汉军. 分析对比奥氮平与利培酮治疗老年精神分裂症的疗效及安全性[J]. 中国医院药学杂志, 2018, 38(15): 1648-1651. |
| [19] | 林春燕, 周红蕊, 黎顺成, 等. 探讨奥氮平对首发精神分裂症伴肥胖患者认知功能、糖脂代谢及相关激素指标水平的影响[J]. 中国医院药学杂志, 2019, 39(9): 954-958. |
| [20] | Love, R.C. and Nelson, M.W. (2000) Pharmacology and Clinical Experience with Risperidone. Expert Opinion on Pharmacotherapy, 1, 1441-1453. https://doi.org/10.1517/14656566.1.7.1441 |
| [21] | 王丹丹, 张晨. 精神分裂症患者认知功能的神经免疫机制及非典型抗精神病药物对其影响的研究进展[J]. 上海交通大学学报(医学版), 2019, 39(7): 795-799. |
| [22] | David, V., Sarah, M., Nicola, S., et al. (2014) Atypical Antipsychotic Aug-mentation in SSRI Treatment Refractory Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis. BMC Psychiatry, 14, Article No. 317.
https://doi.org/10.1186/PREACCEPT-7008391641303716 |
| [23] | 马倩茹, 牛飞, 李元林. 认知行为疗法联合利培酮对男性精神分裂症患者精神症状及认知功能的影响[J]. 国际精神病学杂志, 2023, 50(5): 973-977. |
| [24] | Cor-rell, C.U., Amber, M., Charmi, P., et al. (2022) Systematic Literature Review of Schizophrenia Clinical Practice Guide-lines on Acute and Maintenance Management with Antipsychotics. NPJ Schizophrenia, 8, Article No. 5.
https://doi.org/10.1038/s41537-021-00192-x |
| [25] | Hopkins, S.C., Ajay, O., Courtney, Z., et al. (2022) Depicting Risperidone Safety Profiles in Clinical Trials across Different Diagnoses Using A Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS. Clinical Drug Investigation, 42, 1113-1121. https://doi.org/10.1007/s40261-022-01218-7 |
| [26] | Stefan, L., Alessio, C., Spyridon, S., et al. (2020) Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. The American Journal of Psychiatry, 177, 342-353. https://doi.org/10.1176/appi.ajp.2019.19010034 |
| [27] | Alexander, H., Carl, H., Mahtani, K.R., et al. (2021) Benefits and Harms of Risperidone and Paliperidone for Treatment of Patients with Schizophrenia or Bipolar Disorder: A Meta-Analysis Involving Individual Participant Data and Clinical Study Reports. BMC Medicine, 19, Article No. 195. https://doi.org/10.1186/s12916-021-02062-w |
| [28] | Koblan, K.S., Kent, J., Hopkins, S.C., et al. (2020) A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. The New England Journal of Medicine, 382, 1497-1506. https://doi.org/10.1056/NEJMoa1911772 |
| [29] | Taishiro, K., Katsuhiko, H., Masahiro, N., et al. (2019) Long-Term Effectiveness of Oral Second-Generation Antipsychotics in Patients with Schizophrenia and Related Disor-ders: A Systematic Review and Meta-Analysis of Direct Head-to-Head Comparisons. World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 18, 208- 224. https://doi.org/10.1002/wps.20632 |
| [30] | 曹莉莎, 王继生, 张芳, 等. 利培酮药品不良反应260例分析[J]. 临床合理用药, 2023, 16(26): 41-44+48. |
| [31] | Catarina, C. and Vicente, A.M. (2007) Pharmacogenetics of Risperidone Response and Induced Side Effects. Personalized Medicine, 4, 271-293. https://doi.org/10.2217/17410541.4.3.271 |
| [32] | Agrawal, M., Saraf, S., Saraf, S., et al. (2018) Nose-to-Brain Drug Delivery: An Update on Clinical Challenges and Progress towards Approval of Anti-Alzheimer Drugs. Journal of Controlled Release, 281, 139-177.
https://doi.org/10.1016/j.jconrel.2018.05.011 |
| [33] | 王娟, 马超英, 岳雅君. 对比奥氮平、阿立哌唑和利培酮治疗阿尔茨海默病的临床效果及对认知功能的影响[J]. 中国老年学杂志, 2023, 43(21): 5241-5244. |
| [34] | Chong, H.Y., Teoh, S.L., Wu, D.B., et al. (2016) Global Economic Burden of Schizophrenia: A Systematic Review. Neuropsychiatric Disease and Treatment, 12, 357-373. https://doi.org/10.2147/NDT.S96649 |
| [35] | 林坤河, 刘宵, 陈洁, 等. 武汉市精神分裂症住院患者疾病经济负担分析[J]. 医学与社会, 2022, 35(3): 6-10+20. |
| [36] | (2022) Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry, 9, 137-150.
https://doi.org/10.1016/S2215-0366(21)00395-3 |
| [37] | Renato, F.D., Pasquale, F.D., Raffaele, G., et al. (2021) Current and Emerging Long-Acting Antipsychotics for the Treatment of Schizophrenia. Expert Opinion on Drug Safety, 20, 771-790.
https://doi.org/10.1080/14740338.2021.1910674 |
| [38] | Correll, C.U., Citrome, L., Haddad, P.M., et al. (2016) The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. The Journal of Clinical Psychi-atry, 77, 1-24.
https://doi.org/10.4088/JCP.15032su1 |
| [39] | 黄兢, 唐慧, 伍海姗, 等. 精神分裂症疾病负担及药物治疗现状困境[J]. 中国药物经济学, 2022, 17(11): 16-21+26. |
| [40] | Javier, D.L., Stefan, L. and Celso, A. (2022) Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. Pharmacopsychiatry, 55, 233-245.
https://doi.org/10.1055/a-1854-0185 |
